NAD+ Oral Supplement Pilot Intervention in Adult Females

University of Rhode Island

Status: Enrolling

Conditions: Inflammation; Cognitive Change; Neurodegenerative Diseases

Treatments: Dietary Supplement: Nicotinamide adenine dinucleotide

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT06579209

2087241-4

P20GM103430 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this clinical trial is to learn if Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women who identify as Latina and are between the ages of 40-80. The main questions it aims to answer are:

Will executive function change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving the NAD+ to see if the results differ from those receiving the placebo.

Participants will:

Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Enrollment: 50 estimated patients

Sex: Female

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Identify as Latina, have three or more adverse childhood experiences, and a BMI of 18.5 or above

Exclusion criteria

• Those who are taking hormone medication, pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 3 patient groups

Pre-testing prior to intervention

No Intervention group

Description:

Prior to receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.

Post-testing after intervention

No Intervention group

Description:

After receiving the supplement, either Nicotinamide adenine dinucleotide or the placebo, participants will undergo cognitive testing and a blood draw.

Intervention

Experimental group

Description:

For four weeks, the participant will consume an oral supplement, either Nicotinamide adenine dinucleotide or a placebo.

Treatment:

Dietary Supplement: Nicotinamide adenine dinucleotide